Endogenous digoxin-like substance in liver failure
Lucena, M.I.; Andrade, R.J.; Fraile, J.M.; Alcantara, R.; Gonzalez-Correa, J.A.; De La Cuesta, F.S.
International Journal of Clinical Pharmacology and Therapeutics 32(10): 567-569
1994
ISSN/ISBN: 0946-1965 PMID: 7834165 Document Number: 429146
Digoxin-like immunoreactive substance (DLIS) has been detected in several patient populations that were not receiving digoxin. We therefore studied the sensitivity of EMIT Convenience Pack Digoxin immunoassay to interference by DLIS in patients with liver failure. Serum digoxin was measured in cirrhotic patients with moderate to severe liver failure (Child-Pugh B or C grade), patients with mild liver disease (chronic hepatitis) and matched control patients without liver disease. Excluded were patients taking or who had ever received any cardiac glycoside in the past. Blood samples were obtained by venipuncture and assayed in duplicate. Twenty-two out of 30 cirrhotic patients (73%) showed false-positive results, vs. one of 6 patients (16.7%) with mild liver disease, and 1 of 10 (10%) controls. The serum DLIS level was negatively correlated with prothrombin activity (r = -0.55, p < 0.00011). Digoxin levels must be interpreted carefully in patients with moderate to severe liver failure.